Refractory Gout Study

If you have hard-to-treat, or refractory, gout consider joining the DISSOLVE II clinical research study.

  • Current treatments for refractory gout often cause an unwanted immune response.
  • This can reduce their effectiveness and may lead to serious side effects. 
  • SEL-212 is the first investigational drug designed to treat refractory gout AND prevent an immune response.

About the Clinical Research Study:

Study participants who test positive for COVID-19 will receive at NO COST:
  • Outpatient study-related care that includes follow-up COVID-19 testing.
  • Compensation for study-related time and reimbursement for travel.
  • Opportunity to support COVID-19 research.
The DISSOLVE II Study will assess whether a once-monthly infusion of SEL-212 could help manage the symptoms of gout more effectively over a longer period.


 If you are interested in taking part in the DISSOLVE II Study, we are searching for people who:
  • Are 19–80 years of age (women must not be able to have children)
  • Have ongoing symptoms of gout despite treatment
  • Have experienced 3 or more gout flare-ups within the last 18 months, OR have gouty arthritis OR gout tophi
*There are other criteria that you will need to meet to qualify, which the study team will discuss with you.